Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   BioPharma   /   GTCB - GTC Biotherapeutics - Deel 10

BioPharma« Terug naar discussie overzicht

GTCB - GTC Biotherapeutics - Deel 10

Volgen
2.041 Posts
Pagina: «« 1 ... 98 99 100 101 102 103 »» | Laatste | Omlaag ↓
  3. ludwig mack 3 december 2007 17:02
    quote:

    Beursprofessor. schreef:

    [quote=SkySpam1]

    Professor in de onnozologie, ja!
    Onnozelaar, je kan nog niet defig een Nederlandse zin samenstellen, laat staan ze zonder fouten te
    schrijven. Professor???
    Ga maar terug gaan ouwehoeren in de koffiekamer,
    pinokkio, daar zit je goed, kun je jouw onzin
    rijkelijk laten vloeien.

    Datum xxx Alias

    02 Dec 07 Beursprofessor.
    03 Nov 07 Easymoney.
    20 Okt 07 Zitnooitfout.
    18 Okt 07 nooitfout.

    Vier maal veranderen van alias op 6 weken tijd?!!
    Wat is hier de bedoeling van??

    [/quote]En dat valt een ander eerder vandaag nog aan dat ie te veel bemoeit!? waar bemoeit u zich nu dan zelf weer mee dan!? alias mag je hier 1 keer per dag veranderen dus wat is het probleem nu??
    wat een gedoe zeg, je verschuilen achter speudo's; wordt volwassen.
  6. [verwijderd] 4 december 2007 12:31
    This is the story of two scientists, Meade and Lonberg, who are toiling on the fringes of biotechnology. Their paths crossed 20 years ago, setting them on a quest to alter the age-old partnership between man and beast by mixing genes to concoct new medicines. Since then the two have pursued their goal on separate but parallel tracks. Meade, 59, is now chief scientific officer of Framingham (Mass.)-based GTC Biotherapeutics (GTCB ), which created Sweetheart. Lonberg is scientific director at Medarex Inc. (MEDX ), which is taking a lead in commercializing transgenic mice. www.businessweek.com/magazine/content...

    www.marketwatch.com/News/Story/Story....

    Lonberg and Meade often catch up on the phone and at conferences. The two share a dream of making a drug together -- first generating a life-saving molecule in Lonberg's mice, then mass-producing it in Meade's goats. "Harry and I agree it would be a wonderful collaboration," Lonberg says. And a fitting epilogue to a 20-year history of transgenic beasts and human health care
  8. [verwijderd] 4 december 2007 19:20
    GTC Biotherapeutics, Inc. Obtains FDA Fast Track Designation For ATryn And Permission To Submit Rolling BLATue Sep 4 16:30:00 EDT 2007

    GTC Biotherapeutics, Inc. announced that United States Food and Drug Administration, or FDA, has designated ATryn a 'fast track product' entitled to accelerated FDA review for the hereditary antithrombin deficiency indication. The FDA has also granted the Company permission to submit the associated Biologics License Application, or BLA, for ATryn on a rolling basis. The Company anticipates filing the initial sections with the FDA in the fourth quarter and completing the rolling submission after all clinical data is gathered, analyzed, and available for the BLA, which is planned to be by the end of the first quarter of 2008.

    GTC Biotherapeutics, Inc. And LFB Biotechnologies Developing CD20 Antibody
    Thu Aug 2 16:30:00 EDT 2007

    GTC Biotherapeutics, Inc. and LFB Biotechnologies, a wholly owned subsidiary of LFB S.A. (Laboratoire francais du Fractionnement et des Biotechnologies S.A.), announced that they have initiated development of a transgenically produced CD20 monoclonal antibody under the existing agreement between GTC and LFB Biotechnologies. The resulting product is expected to have target specificity similar to Rituximab (Rituxan, Mabthera) and to have relatively higher antibody dependent cell-mediated cytotoxicity, or ADCC. The existing relevant CD20 antibody patents will expire by 2014. The transgenically produced CD20 antibody is anticipated to be commercially developed for oncology and auto-immune indications. Rituximab is used in the treatment of B-cell non-Hodgkin's lymphoma, B-cell leukemia and rheumatoid arthritis. It is also under investigation for a range of auto-immune conditions such as systemic lupus erythematosus, immune thrombocytopenic purpura, and type-1 diabetes. Rituximab had worldwide sales of nearly $4 billion in 2006 and is projected to have a $5 billion market by 2010.

    GTC Biotherapeutics, Inc. Obtains License to Nuclear Transfer PatentsTue Apr 10 13:00:00 EDT 2007

    GTC Biotherapeutics, Inc. announced that it has been granted a non-exclusive worldwide license from Start Licensing, Inc., a joint venture between Geron Corporation and Exeter Life Sciences, Inc., for the patents and patent applications developed by the Roslin Institute to apply nuclear transfer to the production of therapeutic proteins in the milk of transgenic animals. Nuclear transfer may be utilized, as an alternative to micro-injection, to provide schedule predictability in developing the first animal that incorporates into its genome the transgene for a therapeutic protein to be expressed in milk. Nuclear transfer may also be used to speed the development of large scale transgenic production capacity. Financial terms include an upfront payment of $200,000 to Start and a total of 278,370 shares of GTCB common stock, based on the 10-day average closing price ending April 5, divided equally between Start and Exeter. There will also be a royalty payable to Start for those products developed with the patented nuclear transfer technology. The license agreement remains in place through the last patent to expire, which is expected in 2016 for the currently issued patents.

    GTC Biotherapeutics, Inc. Grants Expanded License To PharmAtheneTue Mar 13 12:01:00 EDT 2007

    GTC Biotherapeutics, Inc. announced that it has entered into an agreement with PharmAthene, Inc. for providing PharmAthene an expanded license to the Company's patent rights, which will support the further development, manufacturing, regulatory approval and commercialization process for PharmAthene's Protexia program. The expanded license agreement includes rights to utilize the Company's transgenic technology in the worldwide development and commercialization of Protexia for all uses. The financial terms of the expanded license agreement were not disclosed.

    GTC Biotherapeutics, Inc. Enters into Process Development and Clinical Supply Manufacturing Services Agreement with PharmAtheneFri Mar 2 21:33:00 EST 2007

    GTC Biotherapeutics, Inc. and PharmAthene, Inc. announced that they have entered into an agreement under which GTC will provide process development and clinical supply manufacturing services for PharmAthene's Protexia program.

    Dat is bij elkaar toch meer waard dan de huidige koers.

    Vriendelijke groet.

  11. [verwijderd] 5 december 2007 14:36
    GTC Biotherapeutics Obtains Licenses to Factor IX, Factor VIII and Fibrinogen

    Last update: 8:30 a.m. EST Dec. 5, 2007Print E-mail RSS Disable Live Quotes


    FRAMINGHAM, Mass., Dec 05, 2007 (BUSINESS WIRE) -- GTC Biotherapeutics, Inc. (GTCB:gtc biotherapeutics inc com
    News, chart, profile, more
    Last: 0.97-0.01-1.02%

    3:57pm 12/04/2007

    Delayed quote dataAdd to portfolio
    Analyst
    Create alertInsider
    Discuss
    Financials
    Sponsored by:
    0.97, -0.01, -1.0%) has entered into a definitive agreement with ProGenetics, LLC, a private company based in Blacksburg, Virginia, to obtain an exclusive license to develop and commercialize ProGenetics' recombinant human factor IX, recombinant human factor VIII, and recombinant human fibrinogen for North America, Europe and Japan. ProGenetics is developing production of the human coagulation factors IX and VIII in the milk of transgenic pigs and has patents that cover the transgenic production of human fibrinogen. ProGenetics will receive a non-exclusive license to GTC's patent in the United States for the transgenic expression of therapeutic proteins in milk to enable the commercial development of these products outside of North America, Europe and Japan. ProGenetics received $500,000 from GTC upon signing of the agreement and will receive approximately $500,000 from GTC in the second quarter of 2008. GTC will also receive a small equity interest in ProGenetics.
    "We are very pleased to work with ProGenetics to add factor IX, factor VIII, and fibrinogen to our portfolio of recombinant coagulation factors," stated Geoffrey F. Cox, Ph.D., GTC's Chairman and Chief Executive Officer. "Together with our program for recombinant human factor VIIa, GTC has a leading position in developing recombinant versions of all the major coagulation factors used to treat hemophilia and potentially other bleeding conditions. Our strategic portfolio of recombinant plasma proteins also includes ATryn(R), our recombinant form of human antithrombin, and recombinant human alpha-1 antitrypsin, establishing a broad franchise in hematology and associated genetic disorders."
    ProGenetics will be responsible for the production of the proteins in the milk of their transgenic pigs. GTC will be responsible for manufacturing, clinical development, regulatory affairs, and commercialization activities in its territories.
    Hemophilia is caused by genetic conditions in which the patients' failure to express enough coagulation factors may lead to excessive bleeding. Type A hemophilia is due to the lack of factor VIII. Type B hemophilia is due to the lack of factor IX. The preferred treatment strategy is to provide supplemental coagulation factors prophylactically to avoid episodes of excessive bleeding. The price and availability of current recombinant coagulation factors often allows for use in only limited indications and markets. The aggregate market for plasma-derived and recombinant factor IX, factor VIII, and fibrinogen products in North America, Europe and Japan is currently estimated to be greater than $3 billion annually.
    About GTC Biotherapeutics, Inc.
    GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. GTC obtained the first approval anywhere in the world for a transgenically produced protein when ATryn(R), a recombinant form of human antithrombin, was approved by the European Commission for use in patients with hereditary antithrombin deficiency undergoing surgical procedures. ATryn(R) is available for commercial sales in the approved indication in Europe. ATryn(R) is undergoing a phase III clinical study in the hereditary antithrombin deficiency indication for the United States. Completion of ATryn(R)'s Biologics License Application is planned for the first half of 2008. GTC's intellectual property includes a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC's transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as those that are required in large volumes. Additional information is available on the GTC web site, www.gtc-bio.com.
    This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the potential for market development of the products developed with ProGenetics and the potential size of the associated markets, as well as the planned timing of the BLA for ATryn(R). Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to, the risks and uncertainties discussed in GTC's most recent Annual Report on Form 10-K and its other periodic reports as filed with the Securities and Exchange Commission, including the uncertainties associated with conducting clinical studies, the risks and uncertainties associated with dependence upon the actions of partners and regulatory agencies, and the uncertainty that GTC will be able to obtain additional revenues and financial resources, including through continuing and new external programs and marketing and strategic partners for some of its internal programs and additional equity financings. GTC cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and GTC undertakes no obligation to update or revise the statements, except as may be required by law.
    SOURCE: GTC Biotherapeutics, Inc.

    www.marketwatch.com/news/story/story....
  13. [verwijderd] 5 december 2007 14:55
    ben bang dat dit niet alles is; an undisclosed global leader kan toch alleen gtcb zijn ?

    Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
    BOTHELL, Wash., Dec. 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that they have entered into a feasibility study with an undisclosed global leader in the production of plasma products, to develop an alternative dosage form of Factor IX protein which is currently administered by injection to control and prevent bleeding in patients with hemophilia B.

    "We look forward to working with our new global partner to evaluate the feasibility of delivering Factor IX without an injection," stated Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech. "Patients with hemophilia B, a result of deficiency in the Factor IX protein, require a lifetime of frequent injections in order to manage their condition. An alternative to these injections would be welcomed by patients and their caregivers."

    Factor IX is a protein produced naturally in the body that helps the blood to form clots. Hemophilia B, also known as Christmas disease, is a condition in which the body does not make enough Factor IX and is treated by injections of the protein. If a person does not have enough Factor IX and becomes injured, the blood will not form clots and they may bleed into and damage muscles and joints

    investor.nastech.com/phoenix.zhtml?c=...
  17. ludwig mack 5 december 2007 15:22
    betwijfel het. dan had het er wel bijgestaan, en dan had men iets met transgeen laten optekenen of gewoon met de naam, want gtcb moet aan de weg timmeren en hoeft niet sluiks iets af te spreken met zo'n p.b.; conclusie; neen. zo zie ik het. wel leuk gevonden trouwens! gr

    quote:

    Beurs-kneus schreef:

    ben bang dat dit niet alles is; an undisclosed global leader kan toch alleen gtcb zijn ?

    Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
    BOTHELL, Wash., Dec. 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that they have entered into a feasibility study with an undisclosed global leader in the production of plasma products, to develop an alternative dosage form of Factor IX protein which is currently administered by injection to control and prevent bleeding in patients with hemophilia B.

    "We look forward to working with our new global partner to evaluate the feasibility of delivering Factor IX without an injection," stated Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech. "Patients with hemophilia B, a result of deficiency in the Factor IX protein, require a lifetime of frequent injections in order to manage their condition. An alternative to these injections would be welcomed by patients and their caregivers."

    Factor IX is a protein produced naturally in the body that helps the blood to form clots. Hemophilia B, also known as Christmas disease, is a condition in which the body does not make enough Factor IX and is treated by injections of the protein. If a person does not have enough Factor IX and becomes injured, the blood will not form clots and they may bleed into and damage muscles and joints

    investor.nastech.com/phoenix.zhtml?c=...

  19. ludwig mack 5 december 2007 15:28
    quote:

    orchid schreef:

    je bent er snel bij, ontvang het net, een prima bericht, dit soort partnerships hebben we nodig.

    Nu kijken wat de koers doet, en wat commentaren zijn.
    goed bericht en een half miljoen is natuurlijk niets, en later nog eens een zelfde bedrag: wat de werkelijk kosten zijn weet ik niet, maar denk dat dat beduidend meer is, en kan men later met verkopen compenseren en winst maken.
  20. [verwijderd] 5 december 2007 15:37
    Press Release Source: GTC Biotherapeutics, Inc.

    GTC Biotherapeutics Obtains Licenses to Factor IX, Factor VIII and Fibrinogen
    Wednesday December 5, 8:30 am ET

    FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) has entered into a definitive agreement with ProGenetics, LLC, a private company based in Blacksburg, Virginia, to obtain an exclusive license to develop and commercialize ProGenetics’ recombinant human factor IX, recombinant human factor VIII, and recombinant human fibrinogen for North America, Europe and Japan. ProGenetics is developing production of the human coagulation factors IX and VIII in the milk of transgenic pigs and has patents that cover the transgenic production of human fibrinogen. ProGenetics will receive a non-exclusive license to GTC’s patent in the United States for the transgenic expression of therapeutic proteins in milk to enable the commercial development of these products outside of North America, Europe and Japan. ProGenetics received $500,000 from GTC upon signing of the agreement and will receive approximately $500,000 from GTC in the second quarter of 2008. GTC will also receive a small equity interest in ProGenetics.

    “We are very pleased to work with ProGenetics to add factor IX, factor VIII, and fibrinogen to our portfolio of recombinant coagulation factors,” stated Geoffrey F. Cox, Ph.D., GTC’s Chairman and Chief Executive Officer. “Together with our program for recombinant human factor VIIa, GTC has a leading position in developing recombinant versions of all the major coagulation factors used to treat hemophilia and potentially other bleeding conditions. Our strategic portfolio of recombinant plasma proteins also includes ATryn®, our recombinant form of human antithrombin, and recombinant human alpha-1 antitrypsin, establishing a broad franchise in hematology and associated genetic disorders.”

    ProGenetics will be responsible for the production of the proteins in the milk of their transgenic pigs. GTC will be responsible for manufacturing, clinical development, regulatory affairs, and commercialization activities in its territories.

    Hemophilia is caused by genetic conditions in which the patients’ failure to express enough coagulation factors may lead to excessive bleeding. Type A hemophilia is due to the lack of factor VIII. Type B hemophilia is due to the lack of factor IX. The preferred treatment strategy is to provide supplemental coagulation factors prophylactically to avoid episodes of excessive bleeding. The price and availability of current recombinant coagulation factors often allows for use in only limited indications and markets. The aggregate market for plasma-derived and recombinant factor IX, factor VIII, and fibrinogen products in North America, Europe and Japan is currently estimated to be greater than $3 billion annually.

2.041 Posts
Pagina: «« 1 ... 98 99 100 101 102 103 »» | Laatste |Omhoog ↑

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
AZERION 1,580 +0,05 +3,27%
ArcelorMittal 23,710 +0,74 +3,22%
RANDSTAD NV 42,020 +1,16 +2,84%
PostNL 0,936 +0,02 +2,24%
Fagron 18,540 +0,40 +2,21%
FASTNED 20,600 +0,40 +1,98%
THEON INTERNAT 13,800 +0,26 +1,92%
Akzo Nobel 60,580 +1,04 +1,75%
Brunel 9,570 +0,15 +1,59%
PROSUS 35,455 +0,56 +1,59%
AMG Critical Materials N.V. 13,200 +0,19 +1,46%
EBUSCO HOLDING 0,937 +0,01 +1,35%
Basic-Fit 21,880 +0,28 +1,30%
B&S Group SA 4,200 +0,04 +1,08%
Aperam 25,760 +0,24 +0,94%
Heineken 66,340 +0,56 +0,85%
VASTNED 27,800 +0,20 +0,72%
INPOST 15,670 +0,11 +0,71%
TKH 35,180 +0,24 +0,69%
Eurocommercial Properties 22,750 +0,15 +0,66%
Accsys 0,537 +0,00 +0,56%
Air France-KLM 7,434 +0,04 +0,51%
Sligro 10,640 +0,04 +0,38%
WDP 19,740 +0,06 +0,30%
AALBERTS NV 33,920 +0,10 +0,30%
ADYEN NV 1.520,400 +4,40 +0,29%
JUST EAT TAKEAWAY 11,825 +0,01 +0,13%
ASR Nederland 46,730 +0,01 +0,02%
JDE PEET'S 16,360 0,00 0,00%
NSI 19,420 0,00 0,00%
TomTom 5,370 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
OCI 11,070 -0,32 -2,85%
HEIJMANS KON 29,500 -0,75 -2,48%
Vopak 43,460 -1,00 -2,25%
SBM Offshore 17,820 -0,41 -2,25%
CM.COM 5,800 -0,13 -2,19%
SHELL PLC 31,285 -0,69 -2,16%
DSM FIRMENICH AG 97,120 -2,04 -2,06%
ASML 700,700 -14,60 -2,04%
KPN 3,522 -0,07 -1,95%
BESI 135,900 -2,35 -1,70%
Flow Traders 23,320 -0,40 -1,69%
Ahold Delhaize 33,440 -0,55 -1,62%
Corbion 22,660 -0,34 -1,48%
NX FILTRATION 2,960 -0,04 -1,33%
ALLFUNDS GROUP 4,974 -0,07 -1,31%
CTP 15,560 -0,18 -1,14%
RELX 46,680 -0,52 -1,10%
Alfen N.V. 12,575 -0,12 -0,95%
UNILEVER PLC 53,960 -0,50 -0,92%
AEX 901,33 -7,78 -0,86%
ACOMO 17,620 -0,14 -0,79%
Avantium 1,766 -0,01 -0,79%
UMG 24,220 -0,19 -0,78%
IMCD 145,000 -0,95 -0,65%
Van Lanschot Kempen NV 46,400 -0,30 -0,64%
Fugro 15,640 -0,08 -0,51%
Sif Holding 12,000 -0,06 -0,50%
ForFarmers 3,285 -0,01 -0,45%
BAM 4,098 -0,02 -0,44%
ABN AMRO BANK N.V. 16,035 -0,07 -0,40%
SIGNIFY NV 22,660 -0,08 -0,35%
Galapagos 22,700 -0,08 -0,35%
ING 16,020 -0,06 -0,35%
Nedap N.V. 58,200 -0,20 -0,34%
ASMI 609,000 -2,00 -0,33%
AMX 831,33 -2,66 -0,32%
RENEWI 9,540 -0,03 -0,31%
Wereldhave 14,040 -0,04 -0,28%
Aegon 6,244 -0,02 -0,26%
Kendrion 9,980 -0,02 -0,20%
ASCX 1.242,80 -2,41 -0,19%
NN Group 42,900 -0,08 -0,19%
Arcadis 55,100 -0,05 -0,09%
Wolters Kluwer 169,350 -0,15 -0,09%
Pharming 0,870 0,00 -0,06%
EXOR NV 90,050 -0,05 -0,06%
Philips Koninklijke 25,610 -0,01 -0,04%
vlag naam koers verschil relatief verschil
AEX 901,33 -7,78 -0,86%
AEX GR 3.535,32 -30,50 -0,86%
Germany40^ 21.362,80 -48,73 -0,23%
FTSE 100 8.502,35 -62,85 -0,73%
Europe50^ 5.209,69 -9,68 -0,19%
US30^ 44.397,40 0,00 0,00%
Nasd100^ 21.772,10 0,00 0,00%
US500^ 6.099,69 0,00 0,00%
Japan225^ 40.479,80 0,00 0,00%
VD-NEW 14,76 +0,11 +0,78%
#/^ Index indications calculated real time, zie disclaimer